New Targets of CAR-T Therapy for B-cell lymphoma

Abstract

B-cell lymphoma is a kind of hematologic malignancy with high morbidity and mortality, which is usually treated by chemoimmunotherapy followed by an autologous transplant. But the traditional therapy usually leads to relapse and refractory. Now FDA has approved four CAR-T cell products that all target CD19 to give relapsed or refractory patients another chance to control cancer. These achievements may thank the CD19, but the CD19 also leads to some problems including the off-tumor effect and antigen escape that result in off-tumor effects and relapses. These problems prevent CAR-T therapy from being widely used in treating B-cell lymphoma. To solve these problems, new targets should be discovered. Scientists have already done a lot of exploration in this area. To give the scientists some directions, this paper will briefly introduce the two problems, the characteristics that are required for the ideal targets, and some ideal future targets which are understudy now.